Patents by Inventor Dawn Cochrane

Dawn Cochrane has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Treatment of Breast Cancer
    Publication number: 20210069154
    Abstract: The disclosure describes compounds useful for treating breast cancers.
    Type: Application
    Filed: January 22, 2020
    Publication date: March 11, 2021
    Inventors: Andrew A. Protter, Jennifer Richer, Dawn Cochrane
  • Treatment of Breast Cancer
    Publication number: 20190262315
    Abstract: The disclosure describes compounds useful for treating breast cancers.
    Type: Application
    Filed: October 24, 2018
    Publication date: August 29, 2019
    Inventors: Andrew A. Protter, Jennifer Richer, Dawn Cochrane
  • Treatment of breast cancer
    Patent number: 10111861
    Abstract: This disclosure describes the use of one or more compounds that fall within the scope of one or more structural formula I, II, III, IV, V, or VI for treating triple negative breast cancer. Compounds useful for treating breast cancer include those compounds of formulae I, II, III, IV, V, or VI that inhibit proliferation of breast cancer cells and/or lead to the death of breast cancer cells, especially triple negative breast cancer.
    Type: Grant
    Filed: December 9, 2016
    Date of Patent: October 30, 2018
    Assignees: Medivation Prostate Therapeutics, Inc., The Regents of the University of Colorado, a Body Corporate
    Inventors: Andrew A. Protter, Jennifer Richer, Dawn Cochrane
  • Treatment of Breast Cancer
    Publication number: 20170087132
    Abstract: This disclosure describes the use of one or more compounds that fall within the scope of one or more structural formula I, II, III, IV, V, or VI for treating triple negative breast cancer. Compounds useful for treating breast cancer include those compounds of formulae I, II, III, IV, V, or VI that inhibit proliferation of breast cancer cells and/or lead to the death of breast cancer cells, especially triple negative breast cancer.
    Type: Application
    Filed: December 9, 2016
    Publication date: March 30, 2017
    Inventors: Andrew A. Protter, Jennifer Richer, Dawn Cochrane
  • Treatment of breast cancer
    Patent number: 9517229
    Abstract: The disclosure describes the use of one or more compounds that fall within the scope of one or more of structural formulae I, II, III, IV, V, or VI for treating triple negative breast Compounds useful for treating breast cancer include those compounds of formulae I, II, III, IV, V, or VI that inhibit proliferation of breast cancer cells and/or lead to the death of breast cancer cells, especially triple negative breast cancer.
    Type: Grant
    Filed: July 27, 2012
    Date of Patent: December 13, 2016
    Assignees: MEDIVATION PROSTATE THERAPEUTICS, INC., THE REGENTS OF THE UNIVERSITY OF COLORADO, A BODY CORPORATE
    Inventors: Andrew A. Protter, Jennifer Richer, Dawn Cochrane
  • TREATMENT OF BREAST CANCER
    Publication number: 20140296312
    Abstract: The disclosure describes the use of one or more compounds that fall within the scope of one or more of structural formulae I, II, III, IV, V, or VI for treating triple negative breast Compounds useful for treating breast cancer include those compounds of formulae I, II, III, IV, V, or VI that inhibit proliferation of breast cancer cells and/or lead to the death of breast cancer cells, especially triple negative breast cancer.
    Type: Application
    Filed: July 27, 2012
    Publication date: October 2, 2014
    Applicants: THE REGENTS OF THE UNIVERSITY OF COLORADO, MEDIVATION PROSTATE THERAPEUTICS, INC.
    Inventors: Andrew A. Protter, Jennifer Richer, Dawn Cochrane
  • MiRNAs dysregulated in triple-negative breast cancer
    Patent number: 8507195
    Abstract: The invention provides methods of diagnosing and treating cancer in a subject. The inventors have identified a series of dysregulated miRNAs that are indicative of triple-negative breast cancer. In some embodiments, the invention further provides for the administration of a cancer therapy to the subject.
    Type: Grant
    Filed: August 16, 2010
    Date of Patent: August 13, 2013
    Assignee: The Regents of the University of Colorado
    Inventors: Jennifer Richer, Dawn Cochrane, Steven M. Anderson
  • MIRNAS DYSREGULATED IN TRIPLE-NEGATIVE BREAST CANCER
    Publication number: 20120214864
    Abstract: The invention provides methods of diagnosing and treating cancer in a subject. The inventors have identified a series of dysregulated miRNAs that are indicative of triple-negative breast cancer. In some embodiments, the invention further provides for the administration of a cancer therapy to the subject.
    Type: Application
    Filed: August 16, 2010
    Publication date: August 23, 2012
    Inventors: Jennifer Richer, Dawn Cochrane, Steven M. Anderson